These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Salvesen HB; Iversen OE; Akslen LA Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742 [TBL] [Abstract][Full Text] [Related]
5. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer. Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354 [TBL] [Abstract][Full Text] [Related]
6. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106 [TBL] [Abstract][Full Text] [Related]
7. Loss of beta-catenin is associated with poor survival in ovarian carcinomas. Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS Int J Gynecol Pathol; 2004 Oct; 23(4):337-46. PubMed ID: 15381903 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. Salvesen HB; Iversen OE; Akslen LA J Clin Oncol; 1999 May; 17(5):1382-90. PubMed ID: 10334522 [TBL] [Abstract][Full Text] [Related]
9. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors. Marques FR; Fonsechi-Carvasan GA; De Angelo Andrade LA; Böttcher-Luiz F Gynecol Oncol; 2004 Jul; 94(1):16-24. PubMed ID: 15262114 [TBL] [Abstract][Full Text] [Related]
11. Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer. Nagy B; Tóth L; Molnár P; Méhes G; Thurzó L; Póka R; Hernádi Z Pathol Res Pract; 2017 Aug; 213(8):915-921. PubMed ID: 28651933 [TBL] [Abstract][Full Text] [Related]
12. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Aune G; Stunes AK; Tingulstad S; Salvesen O; Syversen U; Torp SH Int J Clin Exp Pathol; 2011 Jun; 4(5):444-53. PubMed ID: 21738816 [TBL] [Abstract][Full Text] [Related]
13. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994 [TBL] [Abstract][Full Text] [Related]
14. Abnormal immunoreactivity of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex in premalignant and malignant non-melanocytic skin tumours. Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC J Pathol; 2002 Feb; 196(2):154-62. PubMed ID: 11793366 [TBL] [Abstract][Full Text] [Related]
15. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma]. Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706 [TBL] [Abstract][Full Text] [Related]
16. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Klemi PJ; Pylkkänen L; Kiilholma P; Kurvinen K; Joensuu H Cancer; 1995 Oct; 76(7):1201-8. PubMed ID: 8630898 [TBL] [Abstract][Full Text] [Related]
17. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283 [TBL] [Abstract][Full Text] [Related]